Claudia Cerella Sobolewski, Cyril Dicato, Mario Marc Diederich
Published in
Biochemical Pharmacology
Cyclooxygenase (COX)-2 is a pro-inflammatory immediate early response protein, chronically up-regulated in many pathological conditions. In autoimmune diseases, it is responsible for degenerative effects whereas in cancer, it correlates with poor prognosis. A constitutive expression of COX-2 is triggered since the earliest steps of carcinogenesis. ...
Folmer, Florence Jaspars, Marcel Schumacher, Marc Dicato, Mario Marc Diederich
Published in
Biochemical Pharmacology
Phospholipases A(2) (PLA(2)s) form a family of enzymes catalyzing the hydrolysis of membrane phospholipids into arachidonic acid, which is the major precursor of pro-inflammatory eicosanoids. As a result, PLA(2)s have been considered as potential targets in anti-inflammatory drug discovery. Marine natural products are a rich source of bioactive com...
Marie-Hélène Teiten Francois Gaascht Dicato, Mario Marc Diederich
Published in
Biochemical Pharmacology
Since centuries, natural compounds from plants, animals and microorganisms were used in medicinal traditions to treat various diseases without a solid scientific basis. Recent studies have shown that plants that were used or are still used in the medieval European medicine are able to provide relieve for many diseases including cancer. Here we summ...
Kuntz, Sandra Mazerbourg, Sabine Boisbrun, Michel Grillier-Vuissoz, Isabelle Flament, Stephane Marc Diederich Claudia Cerella
Published in
Biochemical Pharmacology
The use of energy restriction mimetic agents (ERMAs) to selectively target cancer cells addicted to glycolysis could be a promising therapeutic approach. Thiazolidinediones (TZDs) are synthetic agonists of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)γ that were developed to treat type II diabetes. These compounds also disp...
Grigorakaki, Christine Franck Morceau Sébastien Chateauvieux Dicato, Mario Marc Diederich
Published in
Biochemical Pharmacology
Many physiological perturbations can cause anemia. In cancer patients, activation of the immune system leads to the production of proinflammatory cytokines including tumor necrosis factor alpha (TNFα), that have been shown to inhibit red-cell production via poorly understood mechanisms. Treatment of anemia by human recombinant erythropoietin (EPO) ...
Ji, Seungwon Kim, Jaemyun Marc Diederich Barbora Orlikova
Published in
Biochemical Pharmacology
N/A
Claudia Cerella Dicato, Mario Marc Diederich
Published in
Biochemical Pharmacology
Cancer cells depend on an altered energy metabolism characterized by increased rates of both glycolysis and glutaminolysis. Accordingly, corresponding key metabolic enzymes are overexpressed or hyperactivated. As a result, this newly acquired metabolic profile determines most other cancer hallmarks including resistance to cell death. Recent finding...
Flavia Radogna Dicato, Mario Marc Diederich
Published in
Biochemical Pharmacology
Cell death plays an essential role in the development of organs, homeostasis, and cancer. Apoptosis and programmed necrosis are two major types of cell death, characterized by different cell morphology and pathways. Accumulating evidence shows autophagy as a new alternative target to treat tumor resistance. Besides its well-known pro-survival role,...
Morceau, Franck
Published in
Biochemical Pharmacology
Human erythroleukemic K 562 cells were induced to were induced to differentiate along the erythroid lineage by anthracycline antitumor drugs, such as aclacinomycin (ACLA) and doxorubicin (DOX). Subsequent stimulation of heme and globin synthesis led to a differential quantitative expression of hemoglobins. Gower 1 (epsilon2, zeta2) was the major ty...
Published in
Biochemical Pharmacology
